Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 17, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, food effect of ASC50 tablets in healthy adult participants and adult participants with mild to moderate plaque psoriasis.
Trial Details
NCT Number NCT07024602
Lead Sponsor Ascletis Pharma (China) Co., Limited
Conditions Plaque Psoriasis
Enrollment 94 participants
Start Date 2025-06
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-17